Normalizing the bone marrow microenvironment with p38 inhibitor reduces multiple myeloma cell proliferation and adhesion and suppresses osteoclast formation

Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation

1998 • 5,369 citations

Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation

2002 • 3,503 citations

Multiple myeloma

2000 • 2,210 citations

A PROSPECTIVE, RANDOMIZED TRIAL OF AUTOLOGOUS BONE MARROW TRANSPLANTATION AND CHEMOTHERAPY IN MULTIPLE MYELOMA

2013 • 2,176 citations

The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.

2001 • 1,520 citations

The Role of the Wnt-Signaling Antagonist DKK1 in the Development of Osteolytic Lesions in Multiple Myeloma

2003 • 1,491 citations

Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma

1996 • 1,091 citations

Bone Morphogenetic Proteins, Their Antagonists, and the Skeleton

2003 • 869 citations

Cell Adhesion Mediated Drug Resistance (CAM-DR): Role of Integrins and Resistance to Apoptosis in Human Myeloma Cell Lines

1999 • 850 citations

Multiple myeloma: evolving genetic events and host interactions

2002 • 815 citations

Wnt signaling in osteoblasts and bone diseases

2004 • 794 citations

Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6

1989 • 775 citations

Multiple Myeloma: Increasing Evidence for a Multistep Transformation Process

1998 • 761 citations

The p38/RK mitogen-activated protein kinase pathway regulates interleukin-6 synthesis response to tumor necrosis factor.

1996 • 650 citations

Advances in biology of multiple myeloma: clinical applications

2004 • 606 citations

Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B

1996 • 582 citations

Superiority of Tandem Autologous Transplantation Over Standard Therapy for Previously Untreated Multiple Myeloma

1997 • 576 citations

Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications

2001 • 562 citations

Adhesion mechanisms regulating the migration of monocytes

2004 • 552 citations

Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression

2001 • 525 citations

Involvement of p38 Mitogen-activated Protein Kinase Signaling Pathway in Osteoclastogenesis Mediated by Receptor Activator of NF-κB Ligand (RANKL)

2000 • 511 citations

Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias.

1989 • 501 citations

IL-6 stimulates osteoclast-like multinucleated cell formation in long term human marrow cultures by inducing IL-1 release.

1990 • 493 citations

Map kinase signaling pathways and hematologic malignancies

2003 • 433 citations

Molecular mechanisms of novel therapeutic approaches for multiple myeloma

2002 • 431 citations

Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration

2001 • 420 citations

Regulation of Osteoclast Function

1997 • 411 citations

The role of tumor necrosis factor α in the pathophysiology of human multiple myeloma: therapeutic applications

2001 • 398 citations

Allogeneic Bone Marrow Transplantation in Multiple Myeloma

1991 • 389 citations

Macrophage inflammatory protein-1α is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor κB ligand

2001 • 330 citations

Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation

2005 • 318 citations

Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity

2002 • 309 citations

The phosphatidylinositol 3-Kinase, p38, and extracellular signal-regulated kinase pathways are involved in osteoclast differentiation

2002 • 303 citations

B-Type Natriuretic Peptide Exerts Broad Functional Opposition to Transforming Growth Factor-β in Primary Human Cardiac Fibroblasts

2004 • 296 citations

Role for macrophage inflammatory protein (MIP)-1α and MIP-1β in the development of osteolytic lesions in multiple myeloma

2002 • 289 citations

Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma

1995 • 275 citations

Modulation of actin dynamics during stress and physiological stimulation by a signaling pathway involving p38 MAP kinase and heat-shock protein 27

1995 • 264 citations

Mechanisms of bone destruction in multiple myeloma: the importance of an unbalanced process in determining the severity of lytic bone disease.

1989 • 240 citations

Role of the tumor microenvironment in mediating de novo resistance to drugs and physiological mediators of cell death

2003 • 202 citations

Cancer and the Microenvironment

2004 • 188 citations

Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma

2003 • 169 citations

New insights into role of microenvironment in multiple myeloma

2000 • 153 citations

MIP-1α utilizes both CCR1 and CCR5 to induce osteoclast formation and increase adhesion of myeloma cells to marrow stromal cells

2005 • 148 citations

Serum levels of interleukin-6 in multiple myeloma and other hematological disorders: correlation with disease activity and other prognostic parameters

1991 • 139 citations

p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells

2004 • 133 citations

IL-6 Mediates the Effects of IL-1 or TNF, but Not PTHrP or 1,25(OH)2D3, on Osteoclast-like Cell Formation in Normal Human Bone Marrow Cultures

1998 • 124 citations

Targeting p38 MAPK inhibits multiple myeloma cell growth in the bone marrow milieu

2002 • 120 citations

Anti‐myeloma activity of pamidronate in vivo

1998 • 109 citations

TNF-related apoptosis-inducing ligand (TRAIL) blocks osteoclastic differentiation induced by RANKL plus M-CSF

2004 • 108 citations

TRAIL counteracts the proadhesive activity of inflammatory cytokines in endothelial cells by down-modulating CCL8 and CXCL10 chemokine expression and release

2005 • 104 citations

Cytokine, cytokine receptors, transduction signals, and oncogenes in human multiple myeloma.

1995 • 103 citations

Expression of interleukin‐1β and tumour necrosis factor‐α in plasma cells from patients with multiple myeloma

1999 • 95 citations

Advances in Biology and Therapy of Multiple Myeloma

2003 • 93 citations

The tumor microenvironment: focus on myeloma

2003 • 89 citations

The tumor microenvironment as a determinant of drug response and resistance

1999 • 86 citations

GW654652, the pan-inhibitor of VEGF receptors, blocks the growth and migration of multiple myeloma cells in the bone marrow microenvironment

2003 • 84 citations

High-dose busulfan and cyclophosphamide are an effective conditioning regimen for allogeneic bone marrow transplantation in chemosensitive multiple myeloma

1998 • 65 citations

PATHOGENESIS AND MANAGEMENT OF BONE LESIONS IN MULTIPLE MYELOMA

1997 • 65 citations

Multiple Myeloma

2002 • 60 citations

Cytokines (IL-6, TNF-alpha, IL-1alpha) and soluble interleukin-2 receptor as serum tumor markers in multiple myeloma.

1996 • 55 citations

The IL-6 receptor super-antagonist Sant7 enhances antiproliferative and apoptotic effects induced by dexamethasone and zoledronic acid on multiple myeloma cells

2002 • 50 citations

Drug resistance and drug development in multiple myeloma

2002 • 32 citations

Drug resistance and drug development in multiple myeloma

2002 • 29 citations

Bisphosphonate Induced Growth Inhibition of Breast Cancer Cells is Augmented by p38 Inhibition

2003 • 28 citations